Joana Goncalves, an insider at Oruka Therapeutics, Inc. (NASDAQ:ORKA), sold 7,000 shares of the company’s stock on December 19, 2023. The shares were sold at an average price of $30.61, resulting in a total value of $214,270.00. Following this transaction, Goncalves now holds only 1,518 shares, valued at approximately $46,465.98. This sale represents an 82.18% decrease in Goncalves’ ownership of the company’s stock. The transaction was disclosed in a filing with the Securities and Exchange Commission (SEC).
Stock Performance and Market Analysis
On the same day, Oruka Therapeutics opened trading at $31.84. The company has a market capitalization of $1.54 billion, a price-to-earnings ratio of -16.76, and a beta of -0.41. The stock has demonstrated significant volatility, with a fifty-day moving average of $28.46 and a two-hundred-day moving average of $19.57. Over the past year, the stock has reached a low of $5.49 and a high of $32.28.
Oruka Therapeutics recently reported its earnings results on November 12, 2023, announcing a loss of ($0.55) earnings per share (EPS) for the quarter. This figure slightly exceeded analysts’ expectations, which had predicted a loss of ($0.56) EPS. Looking ahead, analysts forecast that the company will post an EPS of –3.41 for the current year.
Analyst Ratings and Future Outlook
Several analysts have recently weighed in on Oruka Therapeutics. Piper Sandler initiated coverage with an “overweight” rating and set a target price of $75.00. Conversely, Weiss Ratings maintained a “sell (d-)” rating in a report from October 8. Other firms, including BTIG Research, have increased their price target, boosting it from $56.00 to $63.00 while assigning a “buy” rating. Jefferies Financial Group and Barclays also began coverage, issuing “buy” ratings with target prices of $45.00 and $48.00, respectively. Overall, one analyst has given a “Strong Buy” rating, seven have issued “Buy” ratings, and one has rated the stock as a “Sell.” The consensus rating is currently categorized as a “Moderate Buy,” with a target price of $48.88.
Oruka Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel peptide-based therapies for oncology. The company utilizes a proprietary stapled peptide platform aimed at selectively disrupting protein–protein interactions that promote tumor growth and immune evasion. Its lead candidate, ONCT-01, is currently undergoing Phase 1 clinical trials for patients with advanced solid tumors, assessing its safety, tolerability, and preliminary efficacy.
Investors and stakeholders in Oruka Therapeutics will be monitoring the company closely as it continues to navigate its clinical developments and market performance.
